Protocol Ledger

NCT04778410 · Phase II · TERMINATED

Study of Magrolimab Combinations in Participants With Myeloid Malignancies

Interventional Phase II clinical trial protocol NCT04778410 sponsored by Gilead Sciences in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-06-28 Enrollment: 54 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04778410
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)54 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04778410
Protocol FieldVerified Registry Value
NCT IdentifierNCT04778410
Consolidated Lead SponsorGilead Sciences
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment54 participants (ACTUAL)
Registered Start Date2021-06-28
WhyStopped ClassificationStrategic / Business / Sponsor Decision

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Gilead Sciences across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI